ICH Stability Requirements and Challenges
Instructor:
Wayland Rushing
Product ID: 704585
- Duration: 60 Min
Why Should You Attend:
Performing stability studies is often considered a routine task in the development cycle. However, if they are not designed and executed properly the results can be disastrous. Ineffective stability programs can lead to an assignment of shortened shelf life and/or delays in regulatory approvals. Given the options outlined in the ICH stability guidance, it is important to understand which options apply and how to implement them for your product.
This presentation will cover the ICH stability requirements, how to design the programs taking into account the drug product specifics and common challenges which can occur during these programs.
Learning Objectives:
- Understanding what are the requirements for ICH stability studies
- Learning the how to design stability programs for your drug product
- Understanding the analytical methods requirements
- How to interpret the data generated by the stability programs
Areas Covered in the Webinar:
- Background and Overview of ICH Q1
- What are the requirements for stability programs
- What are the analytical method requirements, what needs to be measured
- Stability indicating methods – what are they?
- Designing Stability Studies
- Standard programs vs matrixing vs. bracketing
- ANDA stability requirements
- Data Analysis
- Tracking and trending
- OOS vs OOT
- Setting specifications and shelf life
Who Will Benefit:
- Drug Development Professionals
- CMC Analytical
- Stability Managers
- Manufacturing
- Quality Assurance
- Regulatory Affairs
- Program Management
Wayland Rushing
Sr Scientific Advisor, ABC Laboratories
Dr. Wayland Rushing is a technical expert in chemistry, manufacturing and controls (CMC) program design, analytical development and regulatory submissions. Over his 15-year career, he has led CMC development programs for a wide array of biopharmaceuticals, including parenterals, inhalation drugs, and other pharmaceuticals with complex delivery systems.
Dr. Rushing is a subject matter expert in HPLC and GC method development and validation, extractables and leachables program design and regulatory submission requirements; has drafted multiple IND and NDA submissions; and assists ABC clients in responding to FDA deficiency letters. He currently serves on Parenteral Drug Association (PDA) advisory committees for Technology Transfer and Elastomeric Closures and Seals Presentation Summary and was co-author of PDA TR 65, Technology Transfer.
More Training By Experts
Refund Policy
Our refund policy is governed by individual products and services refund policy mentioned against each of offerings. However in absence of specific refund policy of an offering below refund policy will be effective.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time. On-Demand Recording purchases will not be refunded as it is available for immediate streaming. However if you are not able to view the webinar or you have any concern about the content of the webinar please contact us at below email or by call mentioning your feedback for resolution of the matter. We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email [email protected] call +1-888-717-2436 (Toll Free).
